Evidence map›Paper›PMID 26605312›Full record

ReviewAnnals of translational medicine2015

Other targeted drugs in melanoma.

María González-Cao, Jordi Rodón, Niki Karachaliou, Jesús Sánchez, Mariacarmela Santarpia, Santiago Viteri, Sara Pilotto, Cristina Teixidó, Aldo Riso, Rafael Rosell

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Current State of Target Treatment in BRAF Mutated Melanoma.Frontiers in molecular biosciences · 2020
    Review
  5. Article
  6. Review
  7. CD207+/langerin positive dendritic cells in invasive andPostepy dermatologii i alergologii · 2017
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

María González-Cao1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.
Jordi Rodón1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.
Niki Karachaliou1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.
Jesús Sánchez1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.
Mariacarmela Santarpia1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.
Santiago Viteri1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.
Sara Pilotto1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.
Cristina Teixidó1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.
Aldo Riso1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.
Rafael Rosell1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.
Instituto Oncológico Dr. Rosell · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeted therapy drugs are developed against specific molecular alterations on cancer cells. Because they are "targeted" to the tumor, these therapies are more effective and better tolerated than conventional therapies such as chemotherapy. In the last decade, great advances have been made in understanding of melanoma biology and identification of molecular mechanisms involved in malignant transformation of cells. The identification of oncogenic mutated kinases involved in this process provides an opportunity for development of new target therapies. The dependence of melanoma on BRAF-mutant kinase has provided an opportunity for development of mutation-specific inhibitors with high activity and excellent tolerance that are now being used in clinical practice. This marked a new era in the treatment of metastatic melanoma and much research is now ongoing to identify other "druggable" kinases and transduction signaling networking. It is expected that in the near future the spectrum of target drugs for melanoma treatment will increase. Herein, we review the most relevant potential novel drugs for melanoma treatment based on preclinical data and the results of early clinical trials.

Indexed as

Melanomapathwaystargetedtherapy

Identifiers

PMID26605312
PMCPMC4630555
OpenAlexW1828658677

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.